NBTXR-3 is under clinical development by Nanobiotix and currently in Phase II for Melanoma. According to GlobalData, Phase II drugs for Melanoma have a 27% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how NBTXR-3’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
NBTXR-3 is under development for the treatment of head and neck cancer squamous cell carcinoma, soft tissue sarcoma, esophageal cancer, pancreatic ductal adenocarcinoma, esophageal adenocarcinoma, pancreatic cancer, hepatocellular carcinoma, melanoma, renal cell carcinoma, transitional cell cancer (urothelial cell cancer), cervical cancer, triple-negative breast cancer (TNBC), metastatic liver cancer, non-small cell lung cancer, squamous cell carcinoma (SCC) of the oral cavity or oropharynx, laryngeal cancer and hypopharyngeal cancer and solid tumor. It is administered through intratumoral route. The therapeutic candidate is composed of functionalized hafnium oxide nanoparticles. It was also under development for rectal cancer. The drug candidate is a radiation sensitizer.
Nanobiotix designs and manufactures nanomedicines for the treatment of cancer. The company is evaluating its lead product candidate NBTXR3 against soft tissue sarcoma, esophageal, pancreatic, liver, rectal, prostate, head and neck cancers; non-small cell lung cancer (NSCLC); recurrent head and neck, lung and liver metastasis cancers. Its product candidate is a first-in-class radiohancer composed of hafnium oxide nanoparticles and is activated by radiation therapy to destroy tumors. The company markets NBTXR3 under the brand name Hensify in Europe to treat patients with soft tissue sarcoma. It operates in the US, Spain and Germany. Nanobiotix is headquartered in Paris, Ile-de-France, France.
For a complete picture of NBTXR-3’s drug-specific PTSR and LoA scores, buy the report here.